|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycinresistant staphylococcus aureus isolates显示文摘 | Saravolatz LD Pawlak J Johnson LB | 2012 | Clin Infect Dis2012，55，4： | 1 |
| 2 | Methicillinre- sistant Staphylococcus aureus, epidemiologic observations dur- ing a community-acquired outbreak显示文摘 | Saravolatz LD Markowitz M Artfing L | 1982 | Ann Intern Med1982，96，1： | 1 |
| 3 | Telavancin:a novel lipoglycopeptide显示文摘 | SARAVOLATZ LD STEIN GE JOHNSON LB | 2009 | Clin Infect Dis2009，49，12： | 1 |
| 4 | Community-acquired MRSA:Current epidemiology and management issues显示文摘 | Johnson LB Saravolatz LD | 2005 | Infect Med2005，22，： | 1 |
| 5 | Community-acquired methicillin-resistant Staphylococcus aureus infections:a new source for nosocomial outbreaks显示文摘 | Saravolatz LD Pohlod DJ Arking LM | 1982 | Ann Intern Med1982，97，： | 1 |
| 6 | Telavancin:a novel lipoglycopeptide显示文摘 | Saravolatz LD Stein GE Johnson LB | 2009 | Clin Infect Dis2009，49，12： | 1 |
| 7 | Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolone 显示文摘 | SARAVOLATZ LD LEGGETT J | 2003 | Clin Infect Dis2003，37，9： | 1 |
| 8 | Ceftaroline:a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus显示文摘 | Saravolatz LD Stein GE Johnson LB | 2011 | Clin Infect Dis2011，52，9： | 1 |
| 9 | Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus 显示文摘 | SARAVOLATZ LD STEIN GE JOHNSON LB | 2011 | Clin Infect Dis2011，52，9： | 1 |
| 10 | Ceftaroline :a novel cepha- losporin with activity against methicillin-resistant Staphylococcus aureus 显示文摘 | Saravolatz LD Stein GE Johnson LB | 2011 | Clin Infect Dis2011，52，9： | 1 |
| 11 | In vitro activity of LTX-109 a syntheticantimicrobial peptide against MRSA,VISA,VRSA,daptomycinnon-susceptible staphylococcus aureus(DNSSA)and linezolidnon-susceptible SA(LNSSA)显示文摘 | Saravolatz LD Pawlak J Johnson L | 2012 | Antimicrob Agents Chemother2012，56，8： | 1 |
| 12 | Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones显示文摘 | SARAVOLATZ LD LEGGETT J | 2003 | Clin Infect Dis2003，37，9： | 1 |
| 13 | Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones显示文摘 | Saravolatz LD Leggett J | 2003 | Clin Infect Dis2003，37，9： | 1 |
| 14 | Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection显示文摘 | Markowitz N Quinn EL Saravolatz LD | 1992 | Ann Intern Med1992，117，5： | 1 |
| 15 | Community-acquired MRSA:Current epidemiology and management issues显示文摘 | Johnson LB Saravolatz LD | 2005 | Infect Med2005，22，： | 1 |
| 16 | The role of tumor necrosis factor in sepsis显示文摘 | Spooner CE Markow NP Saravolatz LD | 1992 | Clinical Immunology and Immunopathology1992，，： | 1 |
| 17 | In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus 显示文摘 | Saravolatz LD Pawlak J Johnson L | 2012 | Antimicrob Agents Chemother2012，56，8： | 1 |
| 18 | The role of tumor necrosis factor in sepsis显示文摘 | Spooner CE Markow TTZNP Saravolatz LD | 1992 | Clinical Immunology and Immunopathology1992，，： | 1 |
| 19 | Parvovirus B19 infection presenting with necrotizing lymphadenitis 显示文摘 | Johnson LB Pasumarthy A Saravolatz LD | 2003 | Am J Med2003，114，4： | 1 |
| 20 | Telavancin:a novel lipoglycopeptide显示文摘 | Saravolatz LD Stein GE Johnson LB | 2009 | Clinical Infectious Diseases2009，49，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员